RxDoctor Payments Data

Fermina Mazzella, MD

Hematology · Newark, NJNPI 1275522344

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $48,860 of the $49,030 with a category attached, or 99.7%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 99.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $29,760, more than ten times the $17 reported in 2019. Among hematology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,030in general payments, 2019–2025

Across 26 payments — averaging $1885.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$49K
  • Siemens Medical Solutions USA, Inc.$72
  • Roche Diagnostics Corporation$40
  • Phadia US Inc.$30
  • Abbott$17
  • Beckman Coulter, Inc.$12
$40,000in research payments, 2019–2025

Across 2 payments — averaging $20,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Diasorin Inc.$40K

What the payments were for

  • Consulting fees$48,860100%
  • Food & beverage$1700%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$49,030 in reported general payments places this provider in the 95th percentile of 43 hematology providers in New Jersey.

See all hematology providers in New Jersey

Medicare billing

Part B allowed, 2024
$420
Medicare patients
11
Services billed
11

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →